Drug name - Harvoni

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9085573 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

US8334270 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

US8580765 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

US8633309 GILEAD SCIENCES INC Nucleoside phosphoramidates
Mar, 2029

(6 years from now)

US7964580 GILEAD SCIENCES INC NA
Mar, 2029

(6 years from now)

US8822430 GILEAD SCIENCES INC Antiviral compounds
May, 2030

(7 years from now)

US8088368 GILEAD SCIENCES INC Antiviral compounds
May, 2030

(7 years from now)

US9284342 GILEAD SCIENCES INC Nucleoside phosphoramidates
Sep, 2030

(7 years from now)

US8618076 GILEAD SCIENCES INC Nucleoside phosphoramidates
Dec, 2030

(8 years from now)

US10039779 GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jan, 2034

(11 years from now)

CN102906102A GILEAD SCIENCES INC Stereoselective Synthesis Of Phosphorus-Containing Active Matter
Nov, 2015

(6 years ago)

CN104144682A GILEAD SCIENCES INC A Combined Preparation Of Two Antiviral Compounds
Oct, 2016

(5 years ago)

CN104292256A GILEAD SCIENCES INC N - [(2 ' R) -2 '--2 '--2 ' - Methyl-Beta-Phenyl - -5 ' - Uridine Acyl] -L - Alanine 1-Methyl Ethyl Ester And Preparation Method Thereof
Nov, 2018

(3 years ago)

CN105198949A GILEAD SCIENCES INC N-[(2 ' R)-2 '--2 '-Fluorin-2 '-De-Oxide Methyl-[Beta]-Phenyl-5 '-Uridine Acyl]-L-Alanine 1-Methyl Ethyl Ester And Its Preparation Method
Dec, 2019

(2 years ago)

CN104016971A GILEAD SCIENCES INC Antiviral Compounds
May, 2030

(7 years from now)

CN102596936A GILEAD SCIENCES INC Antiviral Compounds
May, 2030

(7 years from now)

CN104230900B GILEAD SCIENCES INC Antiviral Compounds
May, 2030

(7 years from now)

CN103977406B GILEAD SCIENCES INC Antiviral Compound
May, 2030

(7 years from now)

CN102596936B GILEAD SCIENCES INC Antiviral Compounds
May, 2030

(7 years from now)

CN106588890A GILEAD SCIENCES INC Antiviral Compound
May, 2030

(7 years from now)

CN104016971B GILEAD SCIENCES INC Antiviral Compound
May, 2030

(7 years from now)

CN104211713B GILEAD SCIENCES INC Antiviral Compounds
May, 2030

(7 years from now)

CN104211689A GILEAD SCIENCES INC Antiviral Compound
May, 2030

(7 years from now)

CN104211713A GILEAD SCIENCES INC Antiviral Compounds
May, 2030

(7 years from now)

CN106588890B GILEAD SCIENCES INC Antiviral Compounds
May, 2030

(7 years from now)

CN104211689B GILEAD SCIENCES INC Antiviral Compound
May, 2030

(7 years from now)

CN104230900A GILEAD SCIENCES INC Antiviral Compound
May, 2030

(7 years from now)

CN103977406A GILEAD SCIENCES INC Antiviral Compound
May, 2030

(7 years from now)

CN105085592A GILEAD SCIENCES INC N-[(2 ' R)-2 '--2 '-Fluorin-2 '-De-Oxide Methyl-[Beta]-Phenyl-5 '-Uridine Acyl]-L-Alanine 1-Methyl Ethyl Ester And Preparation Method Thereof
May, 2030

(7 years from now)

CN105085592B GILEAD SCIENCES INC N - [(2 ' R) - 2 ' - Deoxy-2 ' - Fluorine-2 ' - Methyl-Beta-Phenyl-5 ' - Uridine Acyl] -L - Lactamine 1-Methyl Ethyl Ester And Its Preparation Method
May, 2030

(7 years from now)

CN102459299A GILEAD SCIENCES INC N- [ (2 ' R) -2 ' -Deoxy-2 ' - Fluoro-2'-Methyl-P-Phenyl-5 ' -Uridylyl] -L-Alanine-1-Methylethyl Ester Process For Its Production
May, 2030

(7 years from now)

CN102459299B GILEAD SCIENCES INC N- [ (2 ' R) -2 ' -Deoxy-2 ' -Fluoro-2 ' -Methyl-P-Phenyl-5 ' -Uridylyl] -L-Alanine 1-Methylethyl Ester And Process For Its Production
May, 2030

(7 years from now)

CN104017020A GILEAD SCIENCES INC Stereoselective Synthesis Of Phosphorus Containing Actives
Mar, 2031

(8 years from now)

CN104017020B GILEAD SCIENCES INC Nucleoside Phosphoramidate
Mar, 2031

(8 years from now)

CN105748499A GILEAD SCIENCES INC Coupling Preparation Of Two Antiviral Compounds
Jan, 2034

(11 years from now)

CN105748499B GILEAD SCIENCES INC A Combined Preparation Of Two Antiviral Compounds
Jan, 2034

(11 years from now)

IN346815B GILEAD SCIENCES INC N-[ (2&Amp;Apos;R) -2&Amp;Apos; Deoxy-2&Amp;Apos;- Fluoro-2&Amp;Apos;-Methyl-Pphenyl- 5&Amp;Apos;-Uridylyl] -L-Alanine 1- Methylethyl Ester And Process For Its Production
May, 2030

(7 years from now)

EP2203462A2 GILEAD SCIENCES INC Nucleoside Phosphoramidate Prodrugs
Jul, 2020

(2 years ago)

EP2203462B1 GILEAD SCIENCES INC Nucleoside Phosphoramidate Prodrugs
Jul, 2020

(2 years ago)

EP2826784B1 GILEAD SCIENCES INC Composition Comprising A Hcv Ns3 Protease Inhibitor And A Phosphoramidate Prodrug Of 2'-Deoxy-2'-Fluoro-2'-C-Methyluridine Nucleoside
Mar, 2028

(5 years from now)

EP2826784A1 GILEAD SCIENCES INC Composition Comprising A Hcv Ns3 Protease Inhibitor And A Phosphoramidate Prodrug Of 2'-Deoxy-2'-Fluoro-2'-C-Methyluridine Nucleoside
Mar, 2028

(5 years from now)

EP3002281B1 GILEAD SCIENCES INC Antiviral Compounds
May, 2030

(7 years from now)

EP3002281A1 GILEAD SCIENCES INC Antiviral Compounds
May, 2030

(7 years from now)

EP3309157A1 GILEAD SCIENCES INC Antiviral Compounds
May, 2030

(7 years from now)

EP2873665A1 GILEAD SCIENCES INC Antiviral Compounds
May, 2030

(7 years from now)

EP3309157B1 GILEAD SCIENCES INC Antiviral Compounds
May, 2030

(7 years from now)

EP2873665B1 GILEAD SCIENCES INC Antiviral Compounds
May, 2030

(7 years from now)

EP2430014B1 GILEAD SCIENCES INC Antiviral Compounds
May, 2030

(7 years from now)

EP2430014A1 GILEAD SCIENCES INC Antiviral Compounds
May, 2030

(7 years from now)

EP2913337A1 GILEAD SCIENCES INC Process For The Production Of Sofosbuvir
May, 2030

(7 years from now)

EP2913337B1 GILEAD SCIENCES INC Process For The Production Of Sofosbuvir
May, 2030

(7 years from now)

EP3321275B1 GILEAD SCIENCES INC Crystalline Form Of Sofosbuvir
May, 2030

(7 years from now)

EP2432792A1 GILEAD SCIENCES INC And Process For The Preparation Of N-[(2'R)-2'-Deoxy-2'-Fluoro-2'-Methyl-P-Phenyl-5'-Uridylyl]-L-Alanine 1-Methylethyl Ester
May, 2030

(7 years from now)

EP2432792B1 GILEAD SCIENCES INC And Process For The Preparation Of N-[(2'R)-2'-Deoxy-2'-Fluoro-2'-Methyl-P-Phenyl-5'-Uridylyl]-L-Alanine 1-Methylethyl Ester
May, 2030

(7 years from now)

EP3321275A1 GILEAD SCIENCES INC Crystalline Form Of Sofosbuvir
May, 2030

(7 years from now)

EP2552931B1 GILEAD SCIENCES INC Stereoselective Synthesis Of Phosphorus Containing Actives
Mar, 2031

(8 years from now)

EP3290428B1 GILEAD SCIENCES INC Tablet Comprising Crystalline (S)-Isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-Dihydropyrimidin-1 (2H)-Yl)-4-Fluoro-3-Hydroxy-4-Methyltetrahydrofuran-2-Yl)Methoxy)(Phenoxy)Phosphoryl)Amino)Propanoate
Mar, 2031

(8 years from now)

EP2552930A2 GILEAD SCIENCES INC Crystalline (S)-Isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-Dihydropyrimidin-1-(2H)-Yl)-4-Fluoro-3-Hydroxy-4-Methyltetrahydrofuran-2-Yl)Methoxy)(Phenoxy)Phosphoryl)Amino)Propanoate
Mar, 2031

(8 years from now)

EP2552930B1 GILEAD SCIENCES INC Crystalline (S)-Isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-Dihydropyrimidin-1-(2H)-Yl)-4-Fluoro-3-Hydroxy-4-Methyltetrahydrofuran-2-Yl)Methoxy)(Phenoxy)Phosphoryl)Amino)Propanoate
Mar, 2031

(8 years from now)

EP2609923A2 GILEAD SCIENCES INC Process For The Crystallisation Of (S)-Isopropyl 2-(((S)-(Perfluorophenoxy)(Phenoxy)Phosphoryl)Amino)Propanoate
Mar, 2031

(8 years from now)

EP2752422A1 GILEAD SCIENCES INC Stereoselective Synthesis Of Phosphorus Containing Actives
Mar, 2031

(8 years from now)

EP3290428A1 GILEAD SCIENCES INC Tablet Comprising Crystalline (S)-Isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-Dihydropyrimidin-1 (2H)-Yl)-4-Fluoro-3-Hydroxy-4-Methyltetrahydrofuran-2-Yl)Methoxy)(Phenoxy)Phosphoryl)Amino)Propanoate
Mar, 2031

(8 years from now)

EP2609923A3 GILEAD SCIENCES INC Nucleoside Phosphoramidates
Mar, 2031

(8 years from now)

EP2752422B1 GILEAD SCIENCES INC Stereoselective Synthesis Of Phosphorus Containing Actives
Mar, 2031

(8 years from now)

EP2609923B1 GILEAD SCIENCES INC Process For The Crystallisation Of (S)-Isopropyl 2-(((S)-(Perfluorophenoxy)(Phenoxy)Phosphoryl)Amino)Propanoate
Mar, 2031

(8 years from now)

EP2552931A2 GILEAD SCIENCES INC Stereoselective Synthesis Of Phosphorus Containing Actives
Mar, 2031

(8 years from now)

EP2950786A1 GILEAD SCIENCES INC Combination Formulation Of Two Antiviral Compounds
Jan, 2034

(11 years from now)

EP2950786B1 GILEAD SCIENCES INC Combination Formulation Of Two Antiviral Compounds
Jan, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8735372 GILEAD SCIENCES INC NA Mar, 2028

(5 years from now)

US8735372

(Pediatric)

GILEAD SCIENCES INC NA Sep, 2028

(5 years from now)

US8580765

(Pediatric)

GILEAD SCIENCES INC NA Sep, 2028

(5 years from now)

US8334270

(Pediatric)

GILEAD SCIENCES INC NA Sep, 2028

(5 years from now)

US9085573

(Pediatric)

GILEAD SCIENCES INC NA Sep, 2028

(5 years from now)

US8889159 GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus Mar, 2029

(6 years from now)

US8633309

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates Sep, 2029

(7 years from now)

US8889159

(Pediatric)

GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus Sep, 2029

(7 years from now)

US7964580

(Pediatric)

GILEAD SCIENCES INC NA Sep, 2029

(7 years from now)

US9511056 GILEAD SCIENCES INC Antiviral compounds May, 2030

(7 years from now)

US8273341 GILEAD SCIENCES INC Antiviral compounds May, 2030

(7 years from now)

US8841278 GILEAD SCIENCES INC Antiviral compounds May, 2030

(7 years from now)

US9511056

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds Nov, 2030

(8 years from now)

US8841278

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds Nov, 2030

(8 years from now)

US8822430

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds Nov, 2030

(8 years from now)

US8088368

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds Nov, 2030

(8 years from now)

US8273341

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds Nov, 2030

(8 years from now)

US9284342

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates Mar, 2031

(8 years from now)

US8618076

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates Jun, 2031

(8 years from now)

US9393256 GILEAD SCIENCES INC Methods for treating HCV Sep, 2032

(9 years from now)

US10456414 GILEAD SCIENCES INC Methods for treating HCV Sep, 2032

(9 years from now)

US9393256

(Pediatric)

GILEAD SCIENCES INC Methods for treating HCV Mar, 2033

(10 years from now)

US10039779

(Pediatric)

GILEAD SCIENCES INC Combination formulation of two antiviral compounds Jul, 2034

(11 years from now)

Drugs and Companies using LEDIPASVIR; SOFOSBUVIR ingredient

Treatment: For the treatment of hepatitis c

Dosage: PELLETS;ORAL

More Information on Dosage
Strength Dosage Availability
33.75MG;150MG/PACKET PELLETS;ORAL Prescription
45MG;200MG/PACKET PELLETS;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.